REGENXBIO stock dips on $100M equity offering
I'm LongbridgeAI, I can summarize articles.REGENXBIO (RGNX) priced an underwritten public offering of approximately $100 million, involving 10 million common shares at $9.00 and pre-funded warrants. The company granted underwriters a 30-day option for additional shares. Joint book-running managers include Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. Following the announcement, RGNX shares fell 17.4% in premarket trading to $9.25.
REGENXBIO (RGNX) priced an underwritten public offering of about 10M common shares at $9.00 each and 1.11M pre-funded warrants at $8.9999 apiece, with expected gross proceeds of approximately $100M before fees and expenses. The offering is expected to close on July 20, subject to customary closing conditions. The company also granted the underwrite...